<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MITOMYCIN</span><br/>(mye-toe-mye'sin)<br/><span class="topboxtradename">Mutamycin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antibiotic</span><br/><b>Prototype: </b>Doxorubicin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 20 mg, 40 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent antibiotic antineoplastic compound. Effective in certain tumors unresponsive to surgery, radiation, or other chemotherapeutic
         agents. Action mechanism unclear but reportedly combines with DNA, thereby interfering with cellular and enzymatic RNA and
         protein synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Highly destructive to rapidly proliferating cells and slowly developing carcinomas.</p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with other chemotherapeutic agents in palliative, adjunctive treatment of disseminated adenocarcinoma of breast,
         pancreas, or stomach, squamous cell carcinoma of head, neck, lung, and cervix. Not recommended to replace surgery or radiotherapy
         or as a single primary therapeutic agent.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity or idiosyncrasy reaction; thrombocytopenia; coagulation disorders or bleeding tendencies; pregnancy (category
         D), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment; myelosuppression.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cancer</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 20 mg/m<sup>2</sup>/d as a single dose q68wk, additional doses based on hematologic response<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li> 						Note: Verify correct IV concentration and rate of infusion/injection for administration to children with physician. 					</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute each 5 mg with 10 mL sterile water for injection. Shake to dissolve. If product does not clear immediately, allow to
                  stand at room temperature until solution is obtained. Reconstituted solution is purple.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give reconstituted solution over 510 min or longer as determined by total volume of solution. Monitor IV site closely.
                  Avoid extravasation to prevent extreme tissue reaction (cellulitis) to the toxic drug.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <span class="classification">dextrose-containing solutions</span>, <b>bleomycin.</b> <span class="incompattype">Y-site:</span> <b>Aztreonam,</b> <b>cefepime,</b> <b>etoposide,</b> <b>filgrastim,</b> <b>gemcitabine,</b> <b>sargramostim,</b> <b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store drug reconstituted with sterile water for injection (0.5 mg/mL) for 14 d refrigerated or 7 d at room temperature. Drug
            diluted in D5W (2040 mcg/mL) is stable at room temperature for 3 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Paresthesias. <span class="typehead">GI:</span> Stomatitis, <span class="speceff-common">nausea, vomiting,</span> anorexia, hematemesis, diarrhea. <span class="typehead">Hematologic:</span> <span class="speceff-life">Bone marrow toxicity</span> (<span class="speceff-common">thrombocytopenia, leukopenia</span> occurring 48 wk after treatment onset), thrombophlebitis, anemia. <span class="typehead">Respiratory:</span> <span class="speceff-life">Acute bronchospasm</span>, hemoptysis, dyspnea, nonproductive cough, pneumonia, <span class="speceff-life">interstitial pneumonitis</span>. <span class="typehead">Skin:</span> Desquamation; induration, pain, necrosis, cellulitis at injection site; reversible alopecia, purple discoloration of nail
      beds. <span class="typehead">Body as a Whole:</span> Pain, headache, fatigue, edema. <span class="typehead">Urogenital:</span> <span class="speceff-life">Hemolytic uremic syndrome</span>, renal toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Metabolized rapidly in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 17 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform WBC with differential, platelet count, PT, INR, aPTT, Hgb, Hct, and serum creatinine frequently during
            and for at least 7 wk after treatment.
         </li>
<li>Do not administer if serum creatinine is &gt;1.7 mg/dL or if platelet count falls below 150,000/mm<sup>3</sup> and WBC is down to 4000/mm<sup>3</sup> or if prothrombin or bleeding times are prolonged.
         </li>
<li>Monitor I&amp;O ratio and pattern. Report any sign of impaired kidney function: Change in ratio, dysuria, hematuria, oliguria,
            frequency, urgency. Keep patient well hydrated (at least 20002500 mL orally daily if tolerated). Drug is nephrotoxic.
         </li>
<li>Observe closely for signs of infection. Monitor body temperature frequently.</li>
<li>Inspect oral cavity daily for signs of stomatitis or superinfection (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report respiratory distress to physician immediately.</li>
<li>Report signs of common cold to physician immediately.</li>
<li>Understand that hair loss is reversible after cessation of treatment.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>